stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) EV/FCF
As of 5 November 2026, BridgeBio Pharma, Inc. (BBIO) trades at a EV/FCF of −39.7×. Over the past ten years it has ranged from −42.5× (July 2026) to −3.5× (May 2022); the current reading is higher than 1% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −34.9× | — |
| FY2024 | −11.6× | — |
| FY2023 | −14.8× | — |
| FY2022 | −5.3× | — |
| FY2021 | −6.4× | — |
| FY2020 | −20.3× | — |
| FY2019 | −12.6× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −35.1× | — |
| Jun 2026 | −35.6× | — |
| Mar 2026 | −34.1× | — |
| Dec 2025 | −34.9× | — |
| 23 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | −40.2× |
| BBIO BridgeBio Pharma, Inc. | −39.7× |
| SMMT Summit Therapeutics PLC compare | −23.1× |
| EXEL Exelixis, Inc. compare | 14.1× |
| HALO Halozyme Therapeutics, Inc. compare | 18.4× |
| JAZZ Jazz Pharmaceuticals PLC compare | 26.2× |
| BMRN BioMarin Pharmaceutical Inc. compare | 26.3× |
| ASND Ascendis Pharma A/S compare | 41.1× |
| TECH Bio-Techne Corp compare | 42.9× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement